desmopressin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vasoconstrictors, vasopressin derivatives 817 16679-58-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desmopressin acetate hydrate
  • minirinmelt
  • desmopressin
  • adiuretin
  • minirin
  • desmopressin acetate
  • DDAVP
A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.
  • Molecular weight: 1069.22
  • Formula: C46H64N14O12S2
  • CLOGP: -3.14
  • LIPINSKI: 3
  • HAC: 26
  • HDO: 14
  • TPSA: 435.41
  • ALOGS: -3.99
  • ROTB: 19

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mcg N
0.40 mg O
4 mcg P
0.24 mg SL

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 47 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 21, 1978 FDA FERRING PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 909.57 46.17 175 373 13150 2344387
Hyponatraemic encephalopathy 213.82 46.17 26 522 56 2357481
Brain injury 104.28 46.17 19 529 900 2356637
Water intoxication 100.08 46.17 14 534 114 2357423
Product prescribing error 82.12 46.17 19 529 2941 2354596
Hyponatraemic seizure 81.83 46.17 11 537 64 2357473
Blood sodium decreased 81.25 46.17 19 529 3081 2354456
Seizure 80.92 46.17 30 518 24436 2333101
Headache 76.53 46.17 41 507 80138 2277399
Flushing 72.20 46.17 23 525 11848 2345689
Epistaxis 55.52 46.17 18 530 9761 2347776
Vomiting 55.45 46.17 32 516 71570 2285967
Hypoosmolar state 47.10 46.17 6 542 21 2357516
Somnolence 46.70 46.17 20 528 23465 2334072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 510.77 52.16 109 373 8891 1737408
Chorioretinopathy 106.07 52.16 18 464 382 1745917
Osmotic demyelination syndrome 74.58 52.16 12 470 180 1746119
Drug ineffective 73.83 52.16 42 440 63759 1682540
Epistaxis 71.87 52.16 23 459 8283 1738016
Water intoxication 70.11 52.16 11 471 139 1746160
Headache 66.41 52.16 32 450 34344 1711955
Seizure 61.59 52.16 26 456 20415 1725884
Inappropriate antidiuretic hormone secretion 58.34 52.16 14 468 1734 1744565
Hyponatraemic encephalopathy 52.45 52.16 7 475 24 1746275

Pharmacologic Action:

SourceCodeDescription
ATC H01BA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
POSTERIOR PITUITARY LOBE HORMONES
Vasopressin and analogues
FDA EPC N0000175916 Factor VIII Activator
FDA PE N0000175914 Increased Coagulation Factor VIII Activity
FDA PE N0000175915 Increased Coagulation Factor VIII Concentration
FDA EPC N0000175905 Vasopressin Analog
FDA CS M0022562 Vasopressins
CHEBI has role CHEBI:59727 vasopressin receptor agonist
CHEBI has role CHEBI:35846 renal agent
CHEBI has role CHEBI:33295 diagnostic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Hereditary factor VIII deficiency disease indication 28293008 DOID:12134
Polyuria indication 28442001
von Willebrand disorder indication 128105004 DOID:12531
Partial Central Diabetes Insipidus indication
Uremic Bleeding Tendency off-label use
Psychogenic polydipsia contraindication 15945005
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic heart failure contraindication 48447003
Upper respiratory infection contraindication 54150009
Allergic rhinitis contraindication 61582004
Nasal discharge contraindication 64531003
Nasal congestion contraindication 68235000
Water intoxication syndrome contraindication 71785001
Hyponatremia contraindication 89627008
Cystic fibrosis contraindication 190905008 DOID:1485
Impaired renal function disorder contraindication 197663003
Finding of excessive fluid intake contraindication 267026004
Hereditary von Willebrand disease type 2B contraindication 359717002
Disorder of coronary artery contraindication 414024009
Severe Allergic Rhinitis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.27 acidic
pKa3 12.64 acidic
pKa4 12.94 acidic
pKa5 13.39 acidic
pKa6 13.43 acidic
pKa7 13.8 acidic
pKa8 10.75 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.00083MG/SPRAY NOCTIVA ALYVANT N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 7405203 May 6, 2023 A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.00083MG/SPRAY NOCTIVA ALYVANT N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 7579321 May 6, 2023 A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.00166MG/SPRAY NOCTIVA ALYVANT N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 7405203 May 6, 2023 A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.00166MG/SPRAY NOCTIVA ALYVANT N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 7579321 May 6, 2023 A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9220747 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9504647 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9919025 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9220747 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9504647 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9919025 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 8802624 Dec. 29, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 8802624 Dec. 29, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 7560429 Feb. 2, 2024 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 7560429 Feb. 2, 2024 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 10137167 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9974826 April 13, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9974826 April 13, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.00083MG/SPRAY NOCTIVA ALYVANT N201656 March 3, 2017 DISCN SPRAY, METERED NASAL March 3, 2020 NEW PRODUCT
0.00166MG/SPRAY NOCTIVA ALYVANT N201656 March 3, 2017 DISCN SPRAY, METERED NASAL March 3, 2020 NEW PRODUCT
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL June 21, 2021 NEW PRODUCT
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL June 21, 2021 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vasopressin V2 receptor GPCR AGONIST Ki 8.30 CHEMBL SCIENTIFIC LITERATURE
Vasopressin V1a receptor GPCR Ki 8.42 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.43 CHEMBL
Oxytocin receptor GPCR AGONIST Ki 7.60 IUPHAR
Vasopressin V2 receptor GPCR Ki 9.10 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.70 CHEMBL
Vasopressin V1a receptor GPCR Ki 7.97 CHEMBL
Oxytocin receptor GPCR Ki 9.01 CHEMBL

External reference:

IDSource
D003894 MESH_DESCRIPTOR_UI
4019709 VUID
N0000170340 NUI
C0011701 UMLSCUI
D00291 KEGG_DRUG
73454001 SNOMEDCT_US
126189002 SNOMEDCT_US
d00583 MMSL
4019709 VANDF
3251 RXNORM
004784 NDDF
CHEMBL376685 ChEMBL_ID
CHEMBL1429 ChEMBL_ID
DB00035 DRUGBANK_ID
CHEMBL1200556 ChEMBL_ID
ENR1LLB0FP UNII
3799 INN_ID
CHEBI:4450 CHEBI
62357-86-2 SECONDARY_CAS_RN
2182 IUPHAR_LIGAND_ID
5311065 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Stimate HUMAN PRESCRIPTION DRUG LABEL 1 0053-6871 SPRAY, METERED 1.50 mg NASAL NDA 14 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2265 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2464 TABLET 0.10 mg ORAL ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2465 TABLET 0.20 mg ORAL ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0615-7549 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 0703-5051 INJECTION 4 ug INTRAVENOUS ANDA 12 sections
Desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 0703-5054 INJECTION 4 ug INTRAVENOUS ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10702-169 TABLET 0.10 mg ORAL ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10702-170 TABLET 0.20 mg ORAL ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 16714-883 TABLET 0.10 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 16714-884 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-489 TABLET 0.10 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-490 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 24208-342 SOLUTION 0.10 mg NASAL ANDA 12 sections
desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-460 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 11 sections
desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-461 INJECTION, SOLUTION 40 ug INTRAVENOUS ANDA 12 sections
DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 43598-931 INJECTION 4 ug SUBCUTANEOUS ANDA 12 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 47335-788 SOLUTION 0.10 mg NASAL ANDA 16 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 50268-220 TABLET 0.10 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 50268-221 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 54868-1129 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5602 SOLUTION 0.10 mg NASAL ANDA 12 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2200 INJECTION 4 ug INTRAVENOUS NDA 12 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2300 INJECTION 4 ug INTRAVENOUS NDA 12 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2400 SPRAY 0.10 mg NASAL NDA 13 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2500 SPRAY 0.10 ug NASAL NDA 18 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2600 TABLET 0.10 mg ORAL NDA 12 sections
DDAVP HUMAN PRESCRIPTION DRUG LABEL 1 55566-2700 TABLET 0.20 mg ORAL NDA 12 sections
NOCDURNA HUMAN PRESCRIPTION DRUG LABEL 1 55566-5050 TABLET 27.70 ug SUBLINGUAL NDA 19 sections
NOCDURNA HUMAN PRESCRIPTION DRUG LABEL 1 55566-5070 TABLET 55.30 ug SUBLINGUAL NDA 19 sections